{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:02:23Z","timestamp":1789768943980,"version":"4.0.1"},"reference-count":134,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.drudis.2026.104797","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:39:39Z","timestamp":1788676779000},"page":"104797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mutant isocitrate dehydrogenase in cancer: Structural biology, small-molecule inhibitors, and future drug discovery strategies"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0420-4364","authenticated-orcid":false,"given":"Moataz A.","family":"Shaldam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8887-2310","authenticated-orcid":false,"given":"Anwar A.","family":"El-Hamaky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourhan A.","family":"Khattab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8313-7586","authenticated-orcid":false,"given":"Salma M.","family":"Hefny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4454-6390","authenticated-orcid":false,"given":"Mohamed S.","family":"Nafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagdy M.","family":"Eldehna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6455-5716","authenticated-orcid":false,"given":"Haytham O.","family":"Tawfik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104797_b0005","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cbpa.2020.06.012","article-title":"Isocitrate dehydrogenase variants in cancer\u2014cellular consequences and therapeutic opportunities","volume":"57","author":"Liu","year":"2020","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.drudis.2026.104797_b0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13578-017-0165-3","article-title":"Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight","volume":"7","author":"Al-Khallaf","year":"2017","journal-title":"Cell Biosci"},{"key":"10.1016\/j.drudis.2026.104797_b0015","doi-asserted-by":"crossref","first-page":"8981","DOI":"10.1021\/acs.jmedchem.8b00159","article-title":"Inhibitors of mutant isocitrate dehydrogenases 1 and 2 (mIDH1\/2): an update and perspective","volume":"61","author":"Ma","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104797_b0020","doi-asserted-by":"crossref","first-page":"5779","DOI":"10.3390\/cancers14235779","article-title":"Wild-type isocitrate dehydrogenase-dependent oxidative decarboxylation and reductive carboxylation in cancer and their clinical significance","volume":"14","author":"He","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104797_b0025","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/jnci\/djq187","article-title":"Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism","volume":"102","author":"Reitman","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.drudis.2026.104797_b0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21037\/cco.2017.06.11","article-title":"Isocitrate dehydrogenase mutation as a therapeutic target in gliomas","volume":"6","author":"Han","year":"2017","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104797_b0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2050-7771-2-18","article-title":"Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C >T have a prognostic value in acute myeloid leukemia","volume":"2","author":"Willander","year":"2014","journal-title":"Biomark Res"},{"key":"10.1016\/j.drudis.2026.104797_b0040","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3390\/cancers11040563","article-title":"Wild-type IDH enzymes as actionable targets for cancer therapy","volume":"11","author":"Bergaggio","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104797_b0045","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41388-021-02056-1","article-title":"Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma","volume":"41","author":"Alzial","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2026.104797_b0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10048-016-0507-z","article-title":"Homozygous mutation p.Pro304His in IDH3A, encoding isocitrate dehydrogenase subunit is associated with severe encephalopathy in infancy","volume":"18","author":"Fattal-Valevski","year":"2017","journal-title":"Neurogenetics"},{"key":"10.1016\/j.drudis.2026.104797_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102695","article-title":"Structures of a constitutively active mutant of human IDH3 reveal new insights into the mechanisms of allosteric activation and the catalytic reaction","volume":"298","author":"Chen","year":"2022","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104797_b0060","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41375-024-02246-2","article-title":"Management of isocitrate dehydrogenase 1\/2 mutated acute myeloid leukemia","volume":"38","author":"Fruchtman","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2026.104797_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117041","article-title":"Comprehensive exploration of isocitrate dehydrogenase (IDH) mutations: tumorigenesis, drug discovery, and covalent inhibitor advances","volume":"282","author":"Gai","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104797_b0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2026.104797_b0075","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tem.2021.11.003","article-title":"Alpha-Ketoglutarate dietary supplementation to improve health in humans","volume":"33","author":"Gyanwali","year":"2022","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.drudis.2026.104797_b0080","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ccell.2018.04.011","article-title":"Biological role and therapeutic potential of IDH mutations in cancer","volume":"34","author":"Waitkus","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2026.104797_b0085","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ijc.24379","article-title":"Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers","volume":"125","author":"Kang","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.drudis.2026.104797_b0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/humu.20937","article-title":"IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors","volume":"30","author":"Bleeker","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.drudis.2026.104797_b0095","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.bbrc.2010.06.125","article-title":"IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastasesto the brain","volume":"398","author":"Lopez","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2026.104797_b0100","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.molmed.2011.06.001","article-title":"Revisiting the TCA cycle: signaling to tumor formation","volume":"17","author":"Raimundo","year":"2011","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.drudis.2026.104797_b0105","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2026.104797_b0110","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104797_b0115","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1236062","article-title":"An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells","volume":"340","author":"Rohle","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104797_b0120","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.1234769","article-title":"Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation","volume":"340","author":"Wang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104797_b0125","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2013-10-533604","article-title":"IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition","volume":"125","author":"Kernytsky","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104797_b0130","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2026.104797_b0135","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature10866","article-title":"IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype","volume":"483","author":"Turcan","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104797_b0140","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104797_b0145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41588-017-0001-z","article-title":"Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence","volume":"50","author":"Turcan","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.drudis.2026.104797_b0150","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104797_b0155","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw4543","article-title":"Cancer-associated mutation and beyond: the emerging biology of isocitrate dehydrogenases in human disease","volume":"5","author":"Tommasini-Ghelfi","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2026.104797_b0160","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1021\/acscatal.5b01928","article-title":"Unveiling the catalytic mechanism of NADP+-dependent isocitrate dehydrogenase with QM\/MM calculations","volume":"6","author":"Neves","year":"2016","journal-title":"ACS Catal"},{"key":"10.1016\/j.drudis.2026.104797_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2023.102672","article-title":"Molecular insights into the catalysis and regulation of mammalian NAD-dependent isocitrate dehydrogenases","volume":"82","author":"Chen","year":"2023","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.drudis.2026.104797_b0170","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/cr.2010.145","article-title":"Molecular mechanisms of \u201coff-on switch\u201d of activities of human IDH1 by tumor-associated mutation R132H","volume":"20","author":"Yang","year":"2010","journal-title":"Cell Res"},{"key":"10.1016\/j.drudis.2026.104797_b0175","doi-asserted-by":"crossref","first-page":"33946","DOI":"10.1074\/jbc.M404298200","article-title":"Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity","volume":"279","author":"Xu","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104797_b0180","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104797_b0185","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/cr.2010.160","article-title":"IDH1 mutant structures reveal a mechanism of dominant inhibition","volume":"20","author":"Zhao","year":"2010","journal-title":"Cell Res"},{"key":"10.1016\/j.drudis.2026.104797_b0190","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.str.2016.12.017","article-title":"Allosteric mutant IDH1 inhibitors reveal mechanisms for IDH1 mutant and isoform selectivity","volume":"25","author":"Xie","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.drudis.2026.104797_b0195","doi-asserted-by":"crossref","first-page":"9785","DOI":"10.1038\/s41598-017-10337-7","article-title":"Studies on the regulatory mechanism of isocitrate dehydrogenase 2 using acetylation mimics","volume":"7","author":"Xu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104797_b0200","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/neuonc\/nov136","article-title":"Isocitrate dehydrogenase mutations in gliomas","volume":"18","author":"Waitkus","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.drudis.2026.104797_b0205","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.18632\/oncotarget.26848","article-title":"Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production","volume":"10","author":"Kotredes","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2026.104797_b0210","doi-asserted-by":"crossref","first-page":"16458","DOI":"10.1038\/s41598-017-16427-w","article-title":"Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2\/R140Q","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104797_b0215","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41421-020-00220-7","article-title":"Structure and allosteric regulation of human NAD-dependent isocitrate dehydrogenase","volume":"6","author":"Sun","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.drudis.2026.104797_b0220","doi-asserted-by":"crossref","first-page":"11120","DOI":"10.1021\/acs.jmedchem.6b01320","article-title":"Discovery and optimization of allosteric inhibitors of mutant isocitrate dehydrogenase 1 (R132H IDH1) displaying activity in human acute myeloid leukemia cells","volume":"59","author":"Jones","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104797_b0225","doi-asserted-by":"crossref","first-page":"7877","DOI":"10.1038\/s41467-024-51692-0","article-title":"Biostructural, biochemical and biophysical studies of mutant IDH1","volume":"15","author":"McCoy","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104797_b0230","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.3390\/molecules28072890","article-title":"Mutated isocitrate dehydrogenase (mIDH) as target for PET imaging in gliomas","volume":"28","author":"Neumaier","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104797_b0235","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s42452-025-07293-7","article-title":"Scaffold modification and synthesis routes for targeting mutant IDH 1: a review","volume":"7","author":"Pai","year":"2025","journal-title":"Discov Appl Sci"},{"key":"10.1016\/j.drudis.2026.104797_b0240","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-019-0173-z","article-title":"Isocitrate dehydrogenase inhibitors in acute myeloid leukemia","volume":"7","author":"Liu","year":"2019","journal-title":"Biomark Res"},{"key":"10.1016\/j.drudis.2026.104797_b0245","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.982424","article-title":"Recent advances of IDH1 mutant inhibitor in cancer therapy","volume":"13","author":"Tian","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104797_b0250","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s43188-025-00284-1","article-title":"Targeting IDH1 mutation-driven Nrf2 signaling to suppress malignant behavior in fibrosarcoma cells","volume":"41","author":"Park","year":"2025","journal-title":"Toxicol Res"},{"key":"10.1016\/j.drudis.2026.104797_b0255","doi-asserted-by":"crossref","DOI":"10.1172\/JCI139542","article-title":"Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice","volume":"131","author":"Kadiyala","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2026.104797_b0260","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.3390\/cancers15112883","article-title":"Mutant IDH in gliomas: role in cancer and treatment options","volume":"15","author":"Solomou","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104797_b0265","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/13543776.2025.2500959","article-title":"A patent review of IDH1 inhibitors (2018-present)","volume":"35","author":"Liang","year":"2025","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.drudis.2026.104797_b0270","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","article-title":"Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers","volume":"9","author":"Popovici-Muller","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104797_b0275","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00259-023-06515-7","article-title":"Radiosynthesis and biological evaluation of [18F]AG-120 for PET imaging of the mutant isocitrate dehydrogenase 1 in glioma","volume":"51","author":"Lai","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.drudis.2026.104797_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105569","article-title":"Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction","volume":"119","author":"Zhou","year":"2022","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104797_b0285","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.70102","article-title":"Reviewing the IDH1 mutation-mediated mechanism of drug resistance and revisiting its overcoming strategies","volume":"105","author":"Wang","year":"2025","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.drudis.2026.104797_b0290","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1016\/j.bmcl.2017.10.029","article-title":"Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors","volume":"27","author":"Zheng","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104797_b0295","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1021\/acsmedchemlett.6b00334","article-title":"Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as allosteric and mutant specific inhibitors of IDH1","volume":"8","author":"Levell","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104797_b0300","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1021\/acsmedchemlett.7b00342","article-title":"Discovery and evaluation of clinical candidate IDH305, a brain penetrant mutant IDH1 inhibitor","volume":"8","author":"Cho","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104797_b0305","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fonc.2019.00417","article-title":"Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics","volume":"9","author":"Golub","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2026.104797_b0310","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1016\/j.bmcl.2018.07.002","article-title":"Discovery and structure-activity-relationship study of novel imidazole cyclopropyl amine analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors","volume":"28","author":"Zheng","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104797_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115464","article-title":"Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma","volume":"257","author":"Wang","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104797_b0320","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1021\/acs.jmedchem.9b01423","article-title":"Structure-based design and identification of FT-2102 (Olutasidenib), a potent mutant-selective IDH1 inhibitor","volume":"63","author":"Caravella","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104797_b0325","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1021\/acs.jmedchem.9b00362","article-title":"Discovery and optimization of quinolinone derivatives as potent, selective, and orally bioavailable mutant isocitrate dehydrogenase 1 (mIDH1) inhibitors","volume":"62","author":"Lin","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104797_b0330","series-title":"Pathogenesis and Treatment of Leukemia","first-page":"147","article-title":"Role of IDH1\/IDH2 Inhibitors in AML","author":"Gill","year":"2023"},{"key":"10.1016\/j.drudis.2026.104797_b0335","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/leu.2017.46","article-title":"Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo","volume":"31","author":"Chaturvedi","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2026.104797_b0340","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1038\/s41375-020-0996-5","article-title":"Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results","volume":"34","author":"Heuser","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2026.104797_b0345","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1158\/1078-0432.CCR-20-4256","article-title":"Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors","volume":"27","author":"Wick","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104797_b0350","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/neuonc\/noac139","article-title":"Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase Ib\/II trial","volume":"25","author":"de la Fuente","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.drudis.2026.104797_b0355","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.CCR-24-2196","article-title":"FDA approval summary: olutasidenib for adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 1 mutation","volume":"31","author":"Woods","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104797_b0360","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/cancers10020049","article-title":"Beyond brooding on oncometabolic havoc in IDH-mutant gliomas and AML: current and future therapeutic strategies","volume":"10","author":"Madala","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104797_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107437","article-title":"Deciphering the multifaceted roles and clinical implications of 2-hydroxyglutarate in cancer","volume":"209","author":"Hao","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2026.104797_b0370","doi-asserted-by":"crossref","first-page":"96735","DOI":"10.1039\/C6RA21617J","article-title":"Identification of a novel selective inhibitor of mutant isocitrate dehydrogenase 1 at allosteric site by docking-based virtual screening","volume":"6","author":"Zou","year":"2016","journal-title":"RSC Adv"},{"key":"10.1016\/j.drudis.2026.104797_b0375","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1074\/jbc.M114.608497","article-title":"Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule","volume":"290","author":"Deng","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104797_b0380","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/neuonc\/nox168.305","article-title":"Exth-09. TDP1\/TOP1 ratio as a predictive indicator for the response of glioblastoma cancer cells to irinotecan treatment","volume":"19","author":"Wang","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.drudis.2026.104797_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101368","article-title":"Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma","volume":"18","author":"Kogiso","year":"2022","journal-title":"Transl Oncol"},{"key":"10.1016\/j.drudis.2026.104797_b0390","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.1021\/acs.jmedchem.3c00203","article-title":"Differentiating inhibition selectivity and binding affinity of isocitrate dehydrogenase 1 variant inhibitors","volume":"66","author":"Liu","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104797_b0395","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1021\/ml400036z","article-title":"Crystallographic investigation and selective inhibition of mutant isocitrate dehydrogenase","volume":"4","author":"Zheng","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104797_b0400","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/lci2.43","article-title":"Current development and future perspective of IDH1 inhibitors in cholangiocarcinoma","volume":"3","author":"Adeva","year":"2022","journal-title":"Liver Cancer Int"},{"key":"10.1016\/j.drudis.2026.104797_b0405","doi-asserted-by":"crossref","first-page":"13750","DOI":"10.1021\/acs.jmedchem.5c00584","article-title":"From inhibitors to PET: SAR-based development of [18F]SK60 for mIDH1 imaging","volume":"68","author":"Kaur","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104797_b0410","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/nchembio.1930","article-title":"New IDH1 mutant inhibitors for treatment of acute myeloid leukemia","volume":"11","author":"Okoye-Okafor","year":"2015","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104797_b0415","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/cancers12030536","article-title":"The landscape of the anti-kinase activity of the IDH1 inhibitors","volume":"12","author":"Malarz","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104797_b0420","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1038\/s41467-022-32436-4","article-title":"Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors","volume":"13","author":"Reinbold","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104797_b0425","doi-asserted-by":"crossref","first-page":"6835","DOI":"10.1038\/s41388-019-0929-9","article-title":"Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma","volume":"38","author":"Nakagawa","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2026.104797_b0430","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3390\/ph17030336","article-title":"Identification of mIDH1 R132C\/S280F inhibitors from natural products by integrated molecular docking, pharmacophore modeling and molecular dynamics simulations","volume":"17","author":"Zhang","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.drudis.2026.104797_b0435","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/neuonc\/noac155","article-title":"The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas","volume":"25","author":"Natsume","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.drudis.2026.104797_b0440","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1021\/acsmedchemlett.6b00264","article-title":"Discovery of 8-membered ring sulfonamides as inhibitors of oncogenic mutant isocitrate dehydrogenase 1","volume":"7","author":"Law","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104797_b0445","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1111\/cas.14152","article-title":"Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants","volume":"110","author":"Gao","year":"2019","journal-title":"Cancer Sci"},{"key":"10.1016\/j.drudis.2026.104797_b0450","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104797_b0455","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-018-0251-7","article-title":"Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations","volume":"559","author":"Intlekofer","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104797_b0460","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1038\/s41467-024-47536-6","article-title":"Wild-type IDH2 is a therapeutic target for triple-negative breast cancer","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104797_b0465","article-title":"Biological roles and therapeutic applications of IDH2 mutations in human cancer","volume":"11","author":"Guo","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2026.104797_b0470","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.apsb.2021.03.005","article-title":"Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2026.104797_b0475","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2022.2157411","article-title":"Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents","volume":"38","author":"Khalil","year":"2023","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.drudis.2026.104797_b0480","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/acsmedchemlett.9b00509","article-title":"Vorasidenib (AG-881): a first-in-class, brain-penetrant dual inhibitor of mutant IDH1 and 2 for treatment of glioma","volume":"11","author":"Konteatis","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104797_b0485","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/cbdd.13139","article-title":"Discovery of a novel class of pyridine derivatives that selectively inhibits mutant isocitrate dehydrogenase 2","volume":"91","author":"Wang","year":"2018","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.drudis.2026.104797_b0490","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1021\/acsmedchemlett.4c00625","article-title":"Discovery of HMPL-306 (Ranosidenib), a new potent and selective dual inhibitor of mutant IDH1 and 2 in clinical development for cancer treatment","volume":"16","author":"Xiao","year":"2025","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104797_b0495","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s40265-024-02097-2","article-title":"Vorasidenib: first approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2026.104797_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116610","article-title":"Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: structure-based virtual screening, biological evaluation and structure-activity relationship study","volume":"275","author":"Xu","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104797_b0505","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2021.39.3_suppl.TPS350","article-title":"A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors","volume":"39","author":"Pauff","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104797_b0510","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1158\/1078-0432.CCR-25-0174","article-title":"Final results from a first-in-human phase I study of the dual isocitrate dehydrogenase (IDH) 1\/2 inhibitor LY3410738 in advanced solid tumors harboring IDH1 or IDH2 mutations","volume":"31","author":"Harding","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104797_b0515","doi-asserted-by":"crossref","first-page":"CT026","DOI":"10.1158\/1538-7445.AM2023-CT026","article-title":"Abstract CT026: a first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies","volume":"83","author":"DiNardo","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104797_b0520","doi-asserted-by":"crossref","first-page":"13717","DOI":"10.1074\/jbc.M113.511030","article-title":"Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1","volume":"289","author":"Davis","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104797_b0525","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-016-0279-9","article-title":"Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives","volume":"9","author":"Song","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2026.104797_b0530","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-18-3749","article-title":"FDA approval summary: ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation","volume":"25","author":"Norsworthy","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104797_b0535","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1021\/acsmedchemlett.8b00182","article-title":"Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as orally bioavailable and brain penetrant mutant IDH1 inhibitors","volume":"9","author":"Zhao","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104797_b0540","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00432-022-03983-6","article-title":"A phase 1 study of IDH305 in patients with IDH1(R132)-mutant acute myeloid leukemia or myelodysplastic syndrome","volume":"149","author":"DiNardo","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104797_b0545","doi-asserted-by":"crossref","first-page":"v145","DOI":"10.1093\/annonc\/mdz243.006","article-title":"Characterization of a novel BBB-permeable mutant IDH1 inhibitor, DS-1001b","volume":"30","author":"Matsunaga","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2026.104797_b0550","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3390\/molecules24050968","article-title":"Consequences of IDH1\/2 mutations in gliomas and an assessment of inhibitors targeting mutated IDH proteins","volume":"24","author":"Kaminska","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104797_b0555","doi-asserted-by":"crossref","first-page":"12758","DOI":"10.1038\/s41598-017-12630-x","article-title":"Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays","volume":"7","author":"Urban","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104797_b0560","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a First-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations","volume":"7","author":"Yen","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2026.104797_b0565","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1016\/j.bbrc.2018.08.068","article-title":"Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2","volume":"503","author":"Ma","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2026.104797_b0570","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104797_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100575","article-title":"HMPL-306 in relapsed or refractory IDH1- and\/or IDH2-mutated acute myeloid leukemia: a phase 1 study","volume":"6","author":"Hu","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.drudis.2026.104797_b0580","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT098","article-title":"Abstract CT098: a first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumors","volume":"83","author":"Rodon","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104797_b0585","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2024-205636","article-title":"Characterizing secondary-site mutations in isocitrate-dehydrogenase-1 (IDH1)","volume":"144","author":"Kandarp","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104797_b0590","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2026.104797_b0595","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41582-024-00967-7","article-title":"IDH inhibition in gliomas: from preclinical models to clinical trials","volume":"20","author":"Rud\u00e0","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.drudis.2026.104797_b0600","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1038\/s41591-025-03884-4","article-title":"Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial","volume":"31","author":"Drummond","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104797_b0605","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41698-024-00646-2","article-title":"Treatment of IDH-mutant glioma in the INDIGO era","volume":"8","author":"Lin","year":"2024","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.drudis.2026.104797_b0610","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11910-024-01378-3","article-title":"The role of mutant IDH inhibitors in the treatment of glioma","volume":"24","author":"Nakhate","year":"2024","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.drudis.2026.104797_b0615","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/17474086.2024.2422554","article-title":"A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS","volume":"17","author":"Norman","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.drudis.2026.104797_b0620","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1 mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104797_b0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2024.110281","article-title":"Degrading mutant IDH1 employing a PROTAC-based approach impairs STAT3 activation","volume":"765","author":"Dutta","year":"2025","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.drudis.2026.104797_b0630","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-021-01434-3","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.drudis.2026.104797_b0635","doi-asserted-by":"crossref","first-page":"7916","DOI":"10.3390\/ijms25147916","article-title":"Clinical implications of isocitrate dehydrogenase mutations and targeted treatment of acute myeloid leukemia with mutant isocitrate dehydrogenase inhibitors\u2014recent advances, challenges and future prospects","volume":"25","author":"Kowalczyk","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104797_b0640","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104797_b0645","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.854352","article-title":"Proteolysis-targeting chimera (PROTAC): is the technology looking at the treatment of brain tumors?","volume":"10","author":"Lospinoso Severini","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.drudis.2026.104797_b0650","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104797_b0655","first-page":"885","article-title":"IDH mutations in Glioma: molecular, cellular, diagnostic, and clinical implications","volume":"13","author":"Choate","year":"2024","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.drudis.2026.104797_b0660","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1158\/1078-0432.CCR-25-4313","article-title":"Ivosidenib and vorasidenib decrease intratumoral 2-hydroxyglutarate and total choline levels in patients with lower-grade glioma: an in vivo MR spectroscopy study","volume":"32","author":"Simicic","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104797_b0665","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/neuonc\/noag028","article-title":"Imaging biomarkers for detecting IDH mutations and monitoring response to novel targeted therapies: current insights and future perspectives","volume":"28","author":"Rajan","year":"2026","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.drudis.2026.104797_b0670","article-title":"Cerebrospinal fluid D-2-hydroxyglutarate for IDH-mutant glioma: utility for detection versus monitoring","author":"Riviere-Cazaux","year":"2025","journal-title":"medRxiv"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:19:56Z","timestamp":1789766396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626002023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":134,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1359644626002023"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104797","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mutant isocitrate dehydrogenase in cancer: Structural biology, small-molecule inhibitors, and future drug discovery strategies","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104797","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104797"}}